The global precision cancer diagnostics tests market was estimated at $3.94 bn in 2018 and is expected to grow at a CAGR of 22.1% during the forecast period. The lung cancer submarket held 23% of the global precision cancer diagnostic tests market in 2018.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 195-page report you will receive 131 tables and 66 figures– all unavailable elsewhere.
The 195-page report provides clear detailed insight into the global checkpoint inhibitors for anti-cancer treatment market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029
• Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029 by Cancer Type:
• Lung Cancer
• Breast Cancer: HER-2 Positive, HR Positive, TNBC
• Colorectal Cancer
• Other Cancers
• Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029 by Biopsy Type:
• Tissue Biopsy
• Liquid Biopsy
• Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029 by Regional and National market:
• US
• Japan
• Germany
• France
• Italy
• UK
• Spain
• China
• India
• Brazil
• Russia
The forecast of each country is further broken down by cancer type and biopsy type.
• Profile of the selected leading companies:
• Abbott Laboratories
• Agilent Technologies, Inc.
• bioMerieux SA
• Genomic Health, Inc.
• Illumina, Inc.
• Myriad Genetics, Inc.
• Qiagen N.V.
• Roche Holding AG
• Siemens Healthineers
• Thermo Fisher Scientific, Inc.
• Analysis of factors that drive and restrain the global precision cancer diagnostics tests market
• Key Questions Answered by this Report:
• How the global precision cancer diagnostic tests market is evolving?
• What are the drivers, restraints and opportunities in the global precision cancer diagnostic tests market?
• How will each of the sub-markets of the precision cancer diagnostic tests market develop over the period of study?
• Who are the leading players in the precision cancer diagnostic tests market and what are their future perspective during the period of study?
• What are the recent developments in the global precision cancer diagnostic tests market?
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Precision Cancer Diagnostics Test Market. You find data, trends and predictions.
Buy our report today Precision Cancer Diagnostic Tests Market Forecasts 2019-2029: Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancer, Gastric Cancer, HER-2 Positive, HR Positive, TNBC, Tissue Biopsy, Liquid Biopsy.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Global Precision Cancer Diagnostic Tests Market Overview
1.2 Why You Should Read This Report
1.3 How the Report Delivers
1.4 Key Questions Answered by This Analytical Report Include
1.5 Who is This Report For?
1.6 Methodology
1.6.1 Primary Research
1.6.2 Secondary Research
1.6.3 Market Evaluation & Forecasting Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
2. Introduction to Precision Medicine
2.1 Evolution and Brief History of Precision Medicine
2.2 Key Benefits of Precision Medicine
2.3 Precision Medicine: Key Application Areas
2.4 Precision Medicine: Key Elements
2.5 Precision Medicine: Different Type of Data Used by Big Data Companies
2.6 Precision Medicine: Area of Interest
3. Qualitative Analysis
3.1 Market Dynamics
3.1.1 Drivers and Opportunities
3.1.1.1 Growing Volume of Precision Cancer Diagnostic Tests Receiving Regulatory Approval
3.1.1.2 Improving Reimbursement Scenario in the Developed Markets
3.1.1.3 Government Support for Precision Medicine
3.1.1.4 Precision Cancer Assays Based on Liquid Biopsies Offer High Growth Opportunities
3.1.1.5 Growing Aging Population and Cancer Prevalence
3.1.2 Restraints and Challenges
3.1.2.1 High Cost of Precision Tests and Therapies
3.1.2.2 Limited Access and Delay in Test Results
3.2 Regulatory Analysis: Precision Diagnostics (Companion Diagnostics)
4. Precision Cancer Diagnostic Tests Market by Cancer Type
4.1 Lung Cancer
4.2 Breast Cancer
4.2.1 HER2 Positive Breast Cancer
4.2.2 Hormone Receptor (HR)-positive Breast Cancer
4.2.3 Triple Negative Breast Cancer
4.3 Colorectal Cancer
4.4 Blood Cancer
4.5 Stomach (Gastric) Cancer
4.6 Other Cancers
5. Precision Cancer Diagnostic Tests Market by Biopsy Method
5.1 Tissue Biopsy
5.2 Liquid Biopsy
6. Leading National Precision Cancer Diagnostic Tests Markets, 2018-2029
6.1 US
6.2 Japan
6.3 Germany
6.4 France
6.6 Italy
6.6 UK
6.7 Spain
6.8 China
6.9 India
6.10 Brazil
6.11 Russia
7. Leading Companies in the Precision Cancer Diagnostic Tests Market
7.1 Roche Holding AG
7.1.1 Roche: Precision Cancer Diagnostics Product Portfolio
7.1.2 Sales and Recent Performance Analysis, 2017
7.1.3 Recent Developments
7.1.3.1 FDA Approval for triple-Negative Breast Cancer Test
7.1.3.2 Collaboration with Phoenix Molecular Designs (PhoenixMD)
7.1.3.3 Partnership with Merck to develop pan-cancer companion diagnostic test
7.1.3.4 Collaboration Agreement with Daiichi Sankyo
7.1.3.5 FDA Approval for cobas EGFR Mutation Test v2 as a companion diagnostic test (CDx) with IRESSA
7.1.3.6 Roche acquires Foundation Medicine
7.1.3.7 Collaboration with Five Prime Therapeutics
7.1.3.8 Extension of Collaboration Agreement with Pierre Fabre
7.1.3.9 FDA Approval for cobas EGFR Mutation Test v2 as a Companion Diagnostic with Tagrisso
7.1.3.10 FDA Approval for Ventana ALK (D5F3) companion diagnostic for Alecensa
7.1.3.11 CE Mark for the VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody
7.1.3.12 FDA Approval for VENTANA ALK (D5F3) CDx Assay
7.1.3.13 FDA Approval for cobas EGFR Mutation Test v2
7.2 Illumina, Inc.
7.2.1 Sales and Recent Performance Analysis, 2017
7.2.2 Illumina: Precision Cancer Diagnostics Product Portfolio
7.2.3 Recent Developments
7.2.3.1 Partnership with Loxo Oncology
7.2.3.2 FDA Approval for Praxis Extended RAS Panel
7.3 Thermo Fisher Scientific, Inc.
7.3.1 Sales and Recent Performance Analysis, 2017
7.3.2 Thermo Fisher: Precision Cancer Diagnostics Product Portfolio
7.3.3 Recent Developments
7.3.3.1 Agreement with Daiichi Sankyo and Takeda Pharmaceutical
7.3.3.2 Companion Diagnostic Partnership with Spectrum Pharmaceuticals, Inc.
7.3.3.3 Companion Diagnostic Development Agreement with Blueprint Medicines
7.3.3.4 Companion Diagnostic Partnership with Agios Pharmaceuticals, Inc.
7.4 Qiagen, N.V.
7.4.1 Sales and Recent Performance Analysis, 2018
7.4.2 Qiagen: Precision Cancer Diagnostics Product Portfolio
7.4.3 Recent Developments
7.4.3.1 Collaboration with Novartis
7.4.3.2 Launch of the QIAscreen HPV PCR Test
7.4.3.3 Launch of Innovative Sample to Insight workflows
7.4.3.4 FDA Approval to Expand Use of EGFR Test
7.4.3.5 Collaboration with Japan’s clinical laboratory testing company, SRL, Inc.
7.4.3.6 Public-private Alliance in the U.K.
7.4.3.7 Launch of AdnaTest Liquid Biopsy Kits in Prostate and Lung Cancer
7.4.3.8 Partnership with Natera
7.4.3.9 Launch of Predictive therascreen PITX2 Test in Europe
7.4.3.10 FDA Clearance for JAK2 Test
7.4.3.11 FDA Approval to Expand Use of EGFR test in Lung Cancer
7.4.3.12 Partnership with Clinical Genomics
7.4.3.13 Partnership with Bristol-Myers Squibb
7.4.3.14 Commercialisation of the Research Use Only AdnaTest Prostate Cancer Panel AR-V7
7.4.3.15 FDA Clearance of JAK2 Test for Leukemia
7.5 Abbott Laboratories
7.5.1 Abbott: Precision Cancer Diagnostics Product Portfolio
7.5.2 Sales and Recent Performance Analysis, 2017
7.5.3 Recent Developments
7.5.3.1 FDA Approvals
7.6 bioMérieux SA
7.6.1 bioMérieux: Precision Cancer Diagnostics Product Portfolio
7.6.3 Recent Developments
7.7 Agilent Technologies, Inc.
7.7.1 Agilent Technologies: Precision Cancer Diagnostics Product Portfolio
7.7.2 Sales and Recent Performance Analysis, 2018
7.7.3 Recent Developments
7.7.3.1 Expanded FDA Approval for Urothelial Carcinoma
7.7.3.2 Expanded FDA Approval for Cervical Cancer
7.7.3.3 Acquisition of Lasergen, Inc.
7.7.3.4 Expanded FDA Approval for Gastric or Gastroesophageal Junction (GEJ) Cancer
7.7.3.5 Expanded FDA Approval for PD-L1 IHC 28-8 pharmDx
7.7.3.6 Introduction of the AriaDx Real-Time PCR System
7.7.3.7 Agreement with Agendia, Inc.
7.8 Siemens Healthineers (A Division of Siemens AG)
7.8.1 Siemens: Precision Cancer Diagnostics Product Portfolio
7.8.2 Sales and Recent Performance Analysis, 2018
7.8.3 Recent Developments
7.9 Myriad Genetics, Inc.
7.9.1 Myriad Genetics: Precision Cancer Diagnostics Product Portfolio
7.9.2 Sales and Recent Performance Analysis, 2017
7.9.3 Recent Developments
7.9.3.1 Expansion of Companion Diagnostic Partnership
7.9.3.2 Approval of BRACAnalysis CDx for Advanced Ovarian Cancer Therapy- Lynparza
7.9.3.3 Approval of BRACAnalysis CDx for advanced ovarian cancer therapy- TALZENNA
7.9.3.4 Laboratory Agreement with Pfizer
7.9.3.5 Approval of BRACAnalysis CDx for Metastatic Breast Cancer Therapy- Lynparza
7.9.3.6 Expanded Research Collaboration with AstraZeneca
7.9.3.7 Companion Diagnostic Collaboration with Clovis Oncology
7.9.3.8 Companion Diagnostic Collaboration with BeiGene
7.10 Genomic Health, Inc.
7.10.1 Genomic Health: Precision Cancer Diagnostics Product Portfolio
7.10.2 Sales and Recent Performance Analysis, 2017
7.10.3 Recent Developments
7.10.3.1 Expansion of Collaboration with Biocartis
7.10.3.2 Launch of Oncotype DX AR-V7 Nucleus Detect
7.10.3.3 Research Collaboration with Janssen Pharmaceuticals
7.10.3.4 Strategic Collaboration with Cleveland Diagnostics
7.10.3.5 Agreement with Biocartis to Develop an Idylla IVD Oncotype DX Breast Cancer Test
8. Conclusions
8.1 The Precision Cancer Diagnostic Tests Market Will Exhibit Lucrative Growth through 2029
8.2 Lung Cancer is the Largest Submarket
8.3 Liquid Biopsy Based Diagnostic Tests Will Offer Significant Growth Opportunities
8.4 Prominent Companies in the Market
8.5 Leading Regional Markets
8.6 Concluding Remarks
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
List of Tables
Table 2.1 Key Benefits of Precision Medicine
Table 2.2 Key Elements of Precision Medicine
Table 4.1 Global Precision Cancer Diagnostic Tests Market by Cancer Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 4.2 Global Precision Cancer Diagnostic Tests Market by Cancer Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 4.3 Global Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue ($m), Market Share (%), 2018 vs. 2024 vs. 2029
Table 4.4 Global Precision Cancer Diagnostic Tests Market for Lung Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 4.5 Global Precision Cancer Diagnostic Tests Market for Lung Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 4.6 Global Precision Cancer Diagnostic Tests Market for Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 4.7 Global Precision Cancer Diagnostic Tests Market for Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 4.8 Global Precision Cancer Diagnostic Tests Market for Breast Cancer by Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 4.9 Global Precision Cancer Diagnostic Tests Market for Breast Cancer by Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 4.10 Global Precision Cancer Diagnostic Tests Market for Breast Cancer by Type: Revenue ($m), Market Share (%), 2018 vs. 2024 vs. 2029
Table 4.11 Global Precision Cancer Diagnostic Tests Market for HER2 Positive Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 4.12 Global Precision Cancer Diagnostic Tests Market for HER2 Positive Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 4.13 Global Precision Cancer Diagnostic Tests Market for HR Positive Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 4.14 Global Precision Cancer Diagnostic Tests Market for HR Positive Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 4.15 Global Precision Cancer Diagnostic Tests Market for TNBC: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 4.16 Global Precision Cancer Diagnostic Tests Market for TNBC: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 4.17 Global Precision Cancer Diagnostic Tests Market for Colorectal Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 4.18 Global Precision Cancer Diagnostic Tests Market for Colorectal Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 4.19 US Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 4.20 US Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 4.21 German Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 4.22 German Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 4.23 US Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 4.24 US Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 4.25 German Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 4.26 German Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 4.27 Global Precision Cancer Diagnostic Tests Market for Other Cancers: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 4.28 Global Precision Cancer Diagnostic Tests Market for Other Cancers: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 5.1 Global Precision Cancer Diagnostic Tests Market by Biopsy Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 5.2 Global Precision Cancer Diagnostic Tests Market by Biopsy Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 5.3 Global Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue ($m), Market Share (%), 2018 vs. 2024 vs. 2029
Table 5.4 Global Precision Cancer Diagnostic Tests Market for Tissue Biopsy: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 5.5 Global Precision Cancer Diagnostic Tests Market for Tissue Biopsy: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 5.6 Global Precision Cancer Diagnostic Tests Market for Liquid Biopsy: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024
Table 5.7 Global Precision Cancer Diagnostic Tests Market for Liquid Biopsy: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029
Table 6.1 Precision Cancer Diagnostic Tests Market: Regional Sales ($m) and Market Shares (%), 2018, 2024 and 2029
Table 6.2 Precision Cancer Diagnostic Tests Market: National and Regional Revenue Forecasts ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.3 Precision Cancer Diagnostic Tests Market: National and Regional Revenue Forecasts ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.4 US Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.5 US Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.6 US Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.7 US Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.8 US Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.9 US Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.10 US Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.11 US Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.12 Japanese Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.13 Japanese Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.14 Japanese Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.15 Japanese Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.16 Japanese Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.17 Japanese Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.18 Japanese Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.19 Japanese Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.20 German Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.21 German Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.22 German Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.23 German Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.24 German Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.25 German Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.26 German Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.27 German Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.28 French Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.29 French Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.30 French Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.31 French Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.32 French Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.33 French Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.34 French Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.35 French Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.36 Italian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.37 Italian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.38 Italian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.39 Italian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.40 Italian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.41 Italian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.42 Italian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.43 Italian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.44 UK Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.45 UK Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.46 UK Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.47 UK Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.48 UK Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.49 UK Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.50 UK Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.51 UK Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.52 Spanish Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.53 Spanish Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.54 Spanish Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.55 Spanish Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.56 Spanish Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.57 Spanish Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.58 Spanish Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.59 Spanish Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.60 Chinese Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.61 Chinese Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.62 Chinese Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.63 Chinese Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.64 Chinese Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.65 Chinese Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.66 Chinese Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.67 Chinese Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.68 Indian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.69 Indian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.70 Indian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.71 Indian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.72 Indian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.73 Indian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.74 Indian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.75 Indian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.76 Brazilian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.77 Brazilian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.78 Brazilian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.79 Brazilian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.80 Brazilian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.81 Brazilian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.82 Brazilian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.83 Brazilian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.84 Russian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.85 Russian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.86 Russian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.87 Russian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.88 Russian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.89 Russian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 6.90 Russian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024
Table 6.91 Russian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029
Table 8.1 Precision Cancer Diagnostic Tests Market: Submarket (Cancer Type) Forecasts ($m) and Market Shares (%), 2018, 2024 and 2029
Table 8.2 Precision Cancer Diagnostic Tests Market: Submarket (Biopsy type) Forecasts ($m) and Market Shares (%), 2018, 2024 and 2029
Table 8.3 Precision Cancer Diagnostic Tests National Market: Revenue Forecasts ($m) and Market Shares (%), 2018, 2024, and 2029
List of Figures
Figure 1.1 Global Precision Cancer Diagnostic Tests Market – Segmentation by Cancer Type
Figure 1.2 Global Precision Cancer Diagnostic Tests Market – Segmentation by Biopsy Method
Figure 1.3 Global Precision Cancer Diagnostic Tests Market – Segmentation by Geography
Figure 2.1 History of Precision Medicine
Figure 2.2 Key Areas of Application of Precision Medicine
Figure 2.3 Key Different Type of Data Used by Big Data Companies in Precision Medicine
Figure 2.4 Key Areas of Interest of Precision Medicine
Figure 4.1 Global Precision Cancer Diagnostic Tests Market for Lung Cancer: Market Forecast Revenue ($m), 2018-2029
Figure 4.2 Global Precision Cancer Diagnostic Tests Market for Breast Cancer: Market Forecast Revenue ($m), 2018-2029
Figure 4.3 Global Precision Cancer Diagnostic Tests Market for HER2 Positive Breast Cancer: Market Forecast Revenue ($m), 2018-2029
Figure 4.4 Global Precision Cancer Diagnostic Tests Market for HR Positive Breast Cancer: Market Forecast Revenue ($m), 2018-2029
Figure 4.5 Global Precision Cancer Diagnostic Tests Market for TNBC: Market Forecast Revenue ($m), 2018-2029
Figure 4.6 Global Precision Cancer Diagnostic Tests Market for Colorectal Cancer: Market Forecast Revenue ($m), 2018-2029
Figure 4.7 US Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), 2018-2029
Figure 4.8 German Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), 2018-2029
Figure 4.9 US Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), 2018-2029
Figure 4.10 German Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), 2018-2029
Figure 4.11 Global Precision Cancer Diagnostic Tests Market for Other Cancers: Market Forecast Revenue ($m), 2018-2029
Figure 5.1 Global Precision Cancer Diagnostic Tests Market for Tissue Biopsy: Market Forecast Revenue ($m), 2018-2029
Figure 5.2 Global Precision Cancer Diagnostic Tests Market for Liquid Biopsy: Market Forecast Revenue ($m), 2018-2029
Figure 6.1 Global Precision Cancer Diagnostic Tests National Market Share (%), 2018
Figure 6.2 Global Precision Cancer Diagnostic Tests National Market Share (%), 2029
Figure 6.3 US Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
Figure 6.4 US Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
Figure 6.5 US Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
Figure 6.6 US Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
Figure 6.7 Japanese Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
Figure 6.8 Japanese Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
Figure 6.9 Japanese Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
Figure 6.10 Japanese Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
Figure 6.11 German Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
Figure 6.12 German Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
Figure 6.13 German Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
Figure 6.14 German Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
Figure 6.15 French Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
Figure 6.16 French Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
Figure 6.17 French Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
Figure 6.18 French Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
Figure 6.19 Italian Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
Figure 6.20 Italian Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
Figure 6.21 Italian Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
Figure 6.22 Italian Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
Figure 6.23 UK Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
Figure 6.24 UK Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
Figure 6.25 UK Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
Figure 6.26 UK Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
Figure 6.27 Spanish Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
Figure 6.28 Spanish Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
Figure 6.29 Spanish Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
Figure 6.30 Spanish Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
Figure 6.31 Chinese Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
Figure 6.32 Chinese Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue, 2018-2029
Figure 6.33 Chinese Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
Figure 6.34 Chinese Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
Figure 6.35 Indian Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
Figure 6.36 Indian Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
Figure 6.37 Indian Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
Figure 6.38 Indian Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
Figure 6.39 Brazilian Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
Figure 6.40 Brazilian Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
Figure 6.41 Brazilian Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
Figure 6.42 Brazilian Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
Figure 6.43 Russian Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029
Figure 6.44 Russian Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029
Figure 6.45 Russian Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029
Figure 6.46 Russian Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
Abbott Laboratories
Agendia, Inc.
Agilent Technologies, Inc.
Agios Pharmaceuticals, Inc.
Alere
Amgen
Amoy Diagnostics
Assurex
AstraZeneca
BeiGene
Biocartis N.V.
bioMérieux SA
Blueprint Medicines Corporation
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Cleveland Diagnostics, Inc.
Clinical Genomics
Clovis Oncology
Daiichi Sankyo
DAKO
DarwinHealth
Epic Sciences, Inc.
Five Prime Therapeutics, Inc.
Foundation Medicine
Genentech
Genomic Health, Inc.
GRAIL, Inc.
HealthWell Foundation
HeiScreen
Helix Holdings
Illumina, Inc.
Invivoscribe
Janssen Pharmaceuticals
Konica Minolta Precision Medicine Japan, Inc.
Lasergen, Inc.
Loxo Oncology
Medgenome
Merck Laboratories
Metafora Biosystems
Myriad Genetic Laboratories
Myriad Genetics, Inc.
NanoString Technologies
Natera
Novartis
Novogene Co.
Pfizer
PhoenixMD
Pierre Fabre
Qiagen, N.V.
Riken Genesis
Roche Holding AG
Siemens Healthineers
Spectrum Pharmaceuticals, Inc.
SRL, Inc.
St. Jude Medical
Strand Lifesciences
Takeda Pharmaceutical
Tarceva
Thermo Fisher Scientific, Inc.
Tianjin Novogene Bioinformatics Technology Company LTD
Xcode Lifesciences
List of Organizations Mentioned in the Report
American Lung Association
American Medical Association
American Society for Clinical Pathology
American Society of Clinical Oncology
Association for Molecular Pathology
Bpifrance
Centers for Medicare & Medicaid Services
Chinese National Medical Products Administration
College of American Pathologists
Columbia University Irving Medical Center
Columbia University Vagelos College of Physicians and Surgeons
European Medicines Agency
Health Innovation Manchester
Heidelberg University Women’s Hospital
Japanese Pharmaceuticals and Medical Device Agency
Ministry of Health, Labor and Welfare
National Cancer Institute
National Coordinator for Health Information Technology
National Institutes of Health
Pharmaceutical and Medical Devices Agency
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
